Program
ABBV-1042
A development code.
In AbbVie's pipeline, M4 Receptor
. Its studies are led by AbbVie.
Furthest: phase 1, since Oct 29, 20251 company-led study, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 10 open or running | phase 1since Oct 29, 2025 | Oct 29, 2025 | none ahead |
- Named in AbbVie’s own pipeline as
ABBV-1042
, phase 1, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2025First study: phase 1 study in Healthy VolunteerFirst studyNCT07222709 · 36 enrolled · United States
TargetBeta
“M4 Receptor”the company's pipeline, read by Claude · source
Other programs on CHRM4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Glycopyrrolaterule | Novartis | phase 4 | 87 |
| xanomelinerule | Bristol-Myers Squibb | phase 4 | 38 |
| emraclidine | AbbVie | phase 2 | 18 |
| GXV-813 | Novartis | phase 2 | 1 |
| BMS-986521 | Bristol-Myers Squibb | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07222709Healthy Volunteer · United States | 1 | Completed | Sep 18, 2026 | 36 |
How it is read
Names in the registry
- “ABBV-1042”, 1 entry
Codes read as this program: ABBV1042.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.